Eledon Pharmaceuticals (ELDN) Stock: Buy, Sell, or Hold?
ELDN - Eledon Pharmaceuticals, Inc. Common Stock
$2.48
0.06 (2.48%)
▲
5d:
-0.4%
30d:
-10.79%
90d:
-35.75%
WAIT
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When ELDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ELDN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ELDN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ELDN is currently trading at $2.48, which is considered oversold relative to its 30-day fair value range of $2.49 to $2.83.
Technical Outlook: Technically, ELDN is in a strong downtrend. Immediate support is located at $2.36, while resistance sits at $2.66.
Market Sentiment: ELDN scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.00 (+262.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELDN is in a strong downtrend. Immediate support is located at $2.36, while resistance sits at $2.66.
Market Sentiment: ELDN scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.00 (+262.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.49 -
$2.83
Company Quality Score
51/100
(HOLD)
Options IV Signal
42th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 42th percentile)
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 262.9% below Wall St target ($9.00)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.49 -
$2.83
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.34
(13.8%)
Support & Resistance Levels
Support Level
$2.36
Resistance Level
$2.66
Current Trend
Strong Downtrend
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.22
Wall Street Target
$9.00
(+262.9%)
Share & Embed Analysis
Last updated: October 12, 2026 4:54 AM ET
Data refreshes hourly during market hours. Next update: 5:54 AM
Data refreshes hourly during market hours. Next update: 5:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1180 | 41 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 63 BUY |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
17 analysts |
$120 | 62 BUY |
